Literature DB >> 35667351

CUA 2022 Annual Meeting Abstracts - Poster Session 9: Oncology - Prostate Sunday, June 26, 2022 • 07:30-09:00.

.   

Abstract

Entities:  

Year:  2022        PMID： 35667351      PMCID： PMC9239725          DOI： 10.5489/cuaj.7931

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   2.052


× No keyword cloud information.
  19 in total

1.  Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?

Authors:  Hillary M Ross; Oleksandr N Kryvenko; Janet E Cowan; Jeffry P Simko; Thomas M Wheeler; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2012-09       Impact factor: 6.394

2.  Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer.

Authors:  Blake B Anderson; Daniel T Oberlin; Aria A Razmaria; Bonnie Choy; Gregory P Zagaja; Arieh L Shalhav; Joshua J Meeks; Ximing J Yang; Gladell P Paner; Scott E Eggener
Journal:  Eur Urol       Date:  2016-12-13       Impact factor: 20.096

3.  The Association Between Sarcopenia and Oncologic Outcomes After Radical Prostatectomy.

Authors:  Ross J Mason; Stephen A Boorjian; Bimal Bhindi; Laureano Rangel; Igor Frank; R Jeffrey Karnes; Matthew K Tollefson
Journal:  Clin Genitourin Cancer       Date:  2017-12-06       Impact factor: 2.872

Review 4.  Salvage Local Treatments After Focal Therapy for Prostate Cancer.

Authors:  Giancarlo Marra; Massimo Valerio; Mark Emberton; Axel Heidenreich; Juanita M Crook; Alberto Bossi; Louis L Pisters
Journal:  Eur Urol Oncol       Date:  2019-04-15

Review 5.  Contemporary role of androgen deprivation therapy for prostate cancer.

Authors:  Vincenzo Pagliarulo; Sergio Bracarda; Mario A Eisenberger; Nicolas Mottet; Fritz H Schröder; Cora N Sternberg; Urs E Studer
Journal:  Eur Urol       Date:  2011-08-19       Impact factor: 20.096

Review 6.  Definition and classification of cancer cachexia: an international consensus.

Authors:  Kenneth Fearon; Florian Strasser; Stefan D Anker; Ingvar Bosaeus; Eduardo Bruera; Robin L Fainsinger; Aminah Jatoi; Charles Loprinzi; Neil MacDonald; Giovanni Mantovani; Mellar Davis; Maurizio Muscaritoli; Faith Ottery; Lukas Radbruch; Paula Ravasco; Declan Walsh; Andrew Wilcock; Stein Kaasa; Vickie E Baracos
Journal:  Lancet Oncol       Date:  2011-02-04       Impact factor: 41.316

7.  Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.

Authors:  Neal D Shore; Fred Saad; Michael S Cookson; Daniel J George; Daniel R Saltzstein; Ronald Tutrone; Hideyuki Akaza; Alberto Bossi; David F van Veenhuyzen; Bryan Selby; Xiaolin Fan; Vicky Kang; Jackie Walling; Bertrand Tombal
Journal:  N Engl J Med       Date:  2020-05-29       Impact factor: 91.245

8.  Incidence of Extraprostatic Extension at Radical Prostatectomy with Pure Gleason Score 3 + 3 = 6 (Grade Group 1) Cancer: Implications for Whether Gleason Score 6 Prostate Cancer Should be Renamed "Not Cancer" and for Selection Criteria for Active Surveillance.

Authors:  Oudai Hassan; Misop Han; Amy Zhou; Adina Paulk; Yue Sun; Abdullah Al-Harbi; Ahmed Alrajjal; Filipa Baptista Dos Santos; Jonathan I Epstein
Journal:  J Urol       Date:  2017-11-15       Impact factor: 7.450

9.  Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.

Authors:  Jinsheng Zhao; Shimiao Zhu; Libin Sun; Fanzheng Meng; Lin Zhao; Yusheng Zhao; Hao Tian; Ping Li; Yuanjie Niu
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

10.  Frailty and Risk of Cardiovascular Diseases in Older Persons: The Age, Gene/Environment Susceptibility-Reykjavik Study.

Authors:  Nicola Veronese; Kristin Sigeirsdottir; Gudny Eiriksdottir; Elisa A Marques; Didier Chalhoub; Caroline L Phillips; Lenore J Launer; Stefania Maggi; Vilmundur Gudnason; Tamara B Harris
Journal:  Rejuvenation Res       Date:  2017-08-07       Impact factor: 4.663
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.